Document Detail

Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck.
MedLine Citation:
PMID:  20451373     Owner:  NLM     Status:  MEDLINE    
To evaluate whether targeting IGF-IR therapeutic can increased chemosensitivity of squamous cell carcinomas of the head and neck (SCCHN) to doxorubicin and cisplatin, Insulin-like growth factor type I receptor (IGF-IR) expression was down-regulated by treatment with AS[S]ODN. Different doses of AS[S]ODN with doxorubicin or cisplatin were tested in TU159 and 183A SCCHN cell lines. Compared to phosphorothioate sense oligonucleotides (SS[S]ODN), AS[S]ODN treatment inhibited cancer cell proliferation and attenuated activation of IGF-IR. AS[S]ODN treatment was shown to enhance the sensitivity of SCCHN cell lines to doxorubicin and cisplatin. This observation correlated closely with the induction of apoptosis as measured by Annexin-V/PI and caspase activation assays. The in vivo results showed that treatment with AS[S]ODN/doxorubicin in combination also resulted in a significant suppression in TU159 xenografts. In conclusion, this study provides evidence for the efficacy of IGF-IR down-regulation combined with chemotherapy and raises the possibility that SCCHN treatment may be improved by pharmaceutical strategies directed towards the IGF-IR.
Shiguo Liu; Fengling Jin; Wuxing Dai; Yongfeng Yu
Related Documents :
16460873 - The effect of progesterone, testosterone and synthetic progestogens on growth factor- a...
8372873 - Expression of functional insulin-like growth factor-i receptors by human amnion cells.
17095273 - Calcium signaling in lizard red blood cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication     Date:  2010-05-05
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  46     ISSN:  1879-0852     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-10     Completed Date:  2010-10-06     Revised Date:  2011-04-06    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  1744-51     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ltd. All rights reserved.
Tongji Medical College, Huazhong University of Science and Technology, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects
Carcinoma, Squamous Cell / drug therapy*
Caspases / metabolism
Cell Communication
Cell Line, Tumor
Cell Proliferation / drug effects
Cisplatin / therapeutic use
Doxorubicin / therapeutic use
Drug Synergism
Head and Neck Neoplasms / drug therapy*
Mice, SCID
Neoplasm Transplantation
Oligonucleotides, Antisense / pharmacology*
Phosphorothioate Oligonucleotides / pharmacology*
Receptor, IGF Type 1 / antagonists & inhibitors*
Vascular Endothelial Growth Factor A / metabolism
Xenograft Model Antitumor Assays
Reg. No./Substance:
0/Antineoplastic Agents; 0/Oligonucleotides, Antisense; 0/Phosphorothioate Oligonucleotides; 0/Vascular Endothelial Growth Factor A; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; EC, IGF Type 1; EC 3.4.22.-/Caspases
Retraction In:
Eur J Cancer. 2011 Mar;47(5):809   [PMID:  21465684 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nasopharyngeal carcinoma: the next challenges.
Next Document:  Performance evaluation of laboratory scale up-flow constructed wetlands with different designs and e...